As another example of therapy-induced activation of alternative pathways, a recent study reported that non-small-cell lung cancer (NSCLC) cells tolerant to EGFR inhibitors display an increased activity of Aurora kinase A (AURKA), mediated by an upregulation of the TPX2 protein. Here, AURKA is linked to non-small cell lung carcinoma.